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Normal human skin is remarkably resistant to infec-
tion from the large numbers of microorganisms that
routinely colonize its surface. In addition to the role
of skin as a mechanical barrier, it has long been
recognized that skin and other epithelia can produce
a range of anti-microbial chemicals that play an
important part in eliminating potential cutaneous
pathogens. Anti-microbial peptides are an important
evolutionarily conserved innate host defense mechan-
ism in many organisms. Human b defensin-1 and -2
are cysteine-rich, cationic, low molecular weight
anti-microbial peptides that have recently been
shown to be expressed in epithelial tissues. In this
study, we describe the characterization of human b
defensin-1 and -2 mRNA and peptide expression in
normal human skin. Using reverse transcription±
polymerase chain reaction we demonstrate that
human b defensin-1 is consistently expressed in skin
samples from various body sites. Human b defensin-2
demonstrates expression that is more variable and is
more readily detectable in facial skin and foreskin
compared with skin from abdomen and breast. In situ
hybridization localizes the human b defensin-1 and -2
transcripts to keratinocytes within interfollicular skin.
Using speci®c antibodies, we have shown that human
b defensin-1 and -2 peptides are localized to the
Malpighian layer of the epidermis and/or stratum
corneum and that there are interindividual and site-
speci®c differences in intensity of immunostaining
and the pattern of peptide localization. The localiz-
ation of human b defensins to the outer layer of the
skin is consistent with the hypothesis that human b
defensins play an essential part in cutaneous innate
immunity. Key words: anti-microbial peptide/innate
immunity/keratinocyte. J Invest Dermatol 117:106±111,
2001
N
ormal human skin is colonized by large numbers
of microorganisms, most of which live harm-
lessly as commensals without causing clinical
disease. In addition to the normal skin ¯ora, the
skin is constantly challenged by pathogens,
which rarely survive long enough to produce evidence of
clinical infection. Whereas the mechanical barrier and drying
effect of normal skin play an important part in the elimination
of potential pathogens from the skin surface, there is evidence
from a number of studies that anti-microbial chemicals
produced either in or on the skin play an important part in
the elimination of microorganisms such as Streptococcus pyogenes
and Staphylococcus aureus (Ricketts et al, 1951). Although sebum-
derived lipids are known to have an anti-microbial effect, the
ef®cient elimination of bacteria from skin that is devoid of
sebaceous glands suggests that human skin produces other
chemicals that contribute to the resistance of the skin to
invasion by microorganisms.
Anti-microbial peptides are evolutionarily conserved elements
of the innate immune system, which show activity against a
wide range of viral, bacterial, and fungal pathogens (Lehrer et al,
1993; Ganz and Lehrer, 1994). Mammalian defensins are
cationic anti-microbial peptides of 29±44 amino acids in length.
The family can be subdivided into two main types based on the
connectivity of the three disul®de bonds between the six
invariant cysteine residues. Human a-defensins have been found
in neutrophils and the Paneth cells of the small intestine
whereas human b defensins (hBD) have been localized to
surface epithelial cells. hBD-1 peptide was initially puri®ed from
human plasma and the amino acid sequence used to clone the
corresponding cDNA (Bensch et al, 1995). Subsequent studies
using reverse transcription±polymerase chain reaction (reverse
transcription±PCR) have shown that hBD-1 is expressed in a
number of epithelial tissues and secretory glands (Zhao et al,
1996). In a preliminary study, we were one of the ®rst to show
that hBD-1 mRNA is expressed in human skin (Fulton et al,
1997). At the same time, some authors reported the isolation of
a second hBD in psoriatic scale (Harder et al, 1997). hBD-2 was
found to be expressed in keratinocytes and normal skin and
mRNA expression was increased following exposure of
keratinocytes to tumor necrosis factor-a, gram-negative and
gram-positive bacteria, and Candida albicans.
The identi®cation of b defensins in epithelial cells and their
putative anti-microbial function has led to speculation that these
peptides are an important ®rst line of defense against infection
in epithelial tissues (McCray and Bentley, 1997; Hiratsuka et al,
1998). In this study, we have investigated the expression of
hBD-1 and hBD-2 mRNA and peptide in normal skin, in
order to elucidate the role of these b defensins in the innate
immune response of human skin.
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MATERIALS AND METHODS
Cultured keratinocytes, cell lines, and tissue samples Normal skin
primary keratinocytes were cultured on 3T3 feeder layers using standard
keratinocyte culture techniques (Rheinwald and Green, 1975). Epithelial
and mesenchymal cell lines were grown in Dulbecco's minimal essential
medium containing 10% bovine fetal serum. Epithelial cell lines included
RTS3b cells (Rapp et al, 1997) and HaCat immortalized epidermal
keratinocytes, which were cultured using conditions similar to those for
normal keratinocytes. Nonepithelial cells included the HT1080 human
®brosarcoma line and normal dermal ®broblasts.
Normal skin samples were obtained from patients undergoing cosmetic
surgical procedures or from excess tissue from unrelated surgical pro-
cedures. Post-mortem skin samples were obtained from various body
sites in order to investigate regional differences in expression within the
same individual. The protocol for use of human material was approved
by the local ethics committee. Samples were either ®xed in paraformal-
dehyde or snap frozen in liquid nitrogen and stored at ± 70°C until
required.
PCR and cloning of ampli®ed fragments Gene-speci®c primers
were designed for both hBD-1 (GenBank accession number U73945)
and hBD-2 (GenBank accession number Z71389). The speci®city of
these primer pairs was ensured by alignment of the cDNA sequences
using the Clustal W technique and regions with minimal sequence
similarity were selected for primer design and probe synthesis. The
regions ampli®ed crossed an intron±exon boundary that allowed
discrimination between ampli®cation from RNA and contaminating
genomic DNA. RNA abundance was normalized using Gli3, which is
an ubiquitously expressed transcription factor in human skin. BamHI and
EcoRI sites were introduced into the forward and reverse hBD1 and
hBD2 primers, respectively, to facilitate cloning. The primers used are
listed:
hBD-1 (U73945), forward (72±86) 5¢-ctcggatccgccATGAGAACTTCC-
TAC-3¢
hBD-1 (U73945), reverse (275±256) 5¢-ctcgaattcCTTGCAGCACTTG-
GCCTTC-3¢
hBD-2 (Z71389), forward (24±39) 5¢-ctcggatccgccATGAGGGTCT-
TGTATC-3¢
hBD-2 (Z71389), reverse (215±193) 5¢-ctcgaattcTGGCTTTTTGCAG-
CATTTTGTTC-3¢
Gli-3, forward, 5¢-gcgaattcGTGCCATCGATGAAACC-3¢
Gli-3, reverse, 5¢-ctaagcttGTCCCTTCTGTTGAGCA-3¢
Total RNA was extracted from snap frozen tissue specimens and
cultured cells using RNazol B (Biogenesis) in accordance with the
manufacturer's instructions. Reverse transcription±PCR was performed
on 1 mg total RNA puri®ed from individual normal skin samples.
Reverse transcription±PCR was carried out using the Access reverse
transcription±PCR kit (Promega) according to the manufacturer's
instructions, with the exception that reactions were carried out in a ®nal
concentration of 0.5 3 reaction buffer. The reverse transcription±PCR
conditions for hBD-1 were: synthesis of ®rst strand cDNA at 48°C for
45 min followed by denaturation at 94°C for 2 min, then 35 cycles of
ampli®cation (94°C for 30 s, 57°C for 30 s, 68°C for 1 min) and a ®nal
extension step at 68°C for 10 min. Reverse transcription±PCR condi-
tions for hBD-2 were similar with an optimal annealing temperature of
55°C. Reaction products were visualized by electrophoresis on agarose
gels. Semi-quantitative reverse transcription±PCR was performed on the
same samples using similar conditions with the exception that the
number of cycles was serially reduced to ensure that the ampli®cation
reaction remained within the linear range.
In order to investigate hBD-1 and hBD-2 expression using in situ
hybridization and northern blot analysis, PCR products were direction-
ally cloned into pGEM3Z (Promega) using appropriate restriction
enzymes and the insert validated by restriction digestion and sequencing
using the ABI 377 system (Perkin Elmer).
Nonradioactive in situ hybridization Digoxigenin-labeled riboprobes
were generated using the digoxigenin RNA labeling kit following the
method provided by the manufacturer (Boehringer). Linearized plasmids
(1 mg) were used for in vitro transcription using digoxigenin-uridine
triphosphate and the transcription catalyzed by SP6 RNA polymerase
and T7 RNA polymerase for the sense and anti-sense orientation,
respectively.
Five-micron paraf®n sections were cut on to Superfrost slides (Merck).
Sections were deparaf®nized followed by treatment with proteinase K at
37°C for 8 min and prehybridization at 42°C. Following this, the
sections were hybridized with 50 ng per ml of digoxigenin-labeled probe
in prehybridization buffer containing dextran sulfate overnight at 42°C
using a Hybaid Omnislide machine. Sections were washed to 3 0.1
sodium citrate/chloride buffer/50% formamide, and then incubated with
anti-digoxigenin-alkaline phosphatase Fab fragments. After rinsing, the
sections were developed with 5-bromo-4-chloro-3-indoyl-phosphate/
nitro blue tetrazolium as chromogenic substrate for alkaline phosphatase.
RNA integrity of ®xed tissue was con®rmed by carrying out hybridiz-
ations using a keratin 14 probe.
Northern blot analysis RNA was isolated from cell lines and cultured
keratinocytes using RNazol B (Biogenesis) in accordance with the
manufacturer's instructions and enriched for poly(A) using a magnetic
bead mRNA Puri®cation kit (Dynal AS, Oslo, Norway). Two
micrograms of polyadenylated RNA extracted from 40 mg of total RNA
was size fractionated on 1% formaldehyde-agarose gels and transferred on
to nylon membranes (HybondTM-XL, Amersham Pharmacia Biotech).
Membranes were then hybridized using the cloned hBD-1 and hBD-2
probes. Transcript size was estimated by comparison with RNA
molecule size standard (Gibco/BRL, Life Technologies). Hybridization
was performed overnight at 42°C. Filters were rinsed brie¯y in
2 3 sodium citrate/chloride buffer and 0.1% sodium dodecyl sulfate then
washed twice for 20 min in 2 3 sodium citrate/chloride buffer and 0.1%
sodium dodecyl sulfate at room temperature. A ®nal wash was performed
in 2 3 sodium citrate/chloride buffer and 0.1% sodium dodecyl sulfate
at 60°C.
Immunohistochemistry For the detection of hBD-1 and hBD-2
peptide in histologic sections, we used rabbit polyclonal antibodies to
hBD-1 and hBD-2, which were kind gifts from Tom Ganz (University
of California, Los Angeles, CA) and Robert Bals (The Wistar Institute,
Philadelphia), respectively. Rabbit preimmune serum was generously
supplied by Tom Ganz. Each of the rabbit polyclonal antibodies had
previously been shown by western blot analysis speci®cally to detect
synthetic and native hBD-1 (Valore et al, 1998) and hBD-2 (Bals et al,
1998). The speci®city of each antibody was investigated using dot blots
with synthetic and biologic peptide. Brie¯y, 1 mg of peptide was dotted
on to Immobilon-P (Millipore). Following protein transfer, the
membrane was blocked with Tris buffer, pH 7.6, containing 10% nonfat
dried milk and incubated overnight with 1:1500 dilution of anti-hBD-1
or anti-hBD-2 antibody. Following two buffer washes of the membrane,
1:1000 dilution of secondary horseradish peroxidase labeled goat anti-
rabbit antibody (Vector Laboratories) was applied for 1 h at room
temperature, before washing twice with buffer. Peptide signal was
detected using enhanced chemiluminescence (ECL Plus kit, Amersham
Pharmacia Biotech).
For three-layer immunostaining, paraformaldehyde-®xed tissue was
embedded in paraf®n and 5 mm wax sections prepared. The sections
were deparaf®nized and rehydrated through a graded series of ethanol
before staining. Antibody localization was by avidin±biotin peroxidase
using standard technique. After blocking endogenous peroxidase activity
with 3% hydrogen peroxide in methanol for 10 min, sections were
blocked with Tris buffer, pH 7.6, containing horse serum. They were
then incubated overnight (4°C) with 1:1500 dilution of anti-hBD-1,
anti-hBD-2, or preimmune rabbit serum (negative control). The sections
were washed twice in buffer, then universal secondary antibody conju-
gated to biotin (VECTASTAIN Universal kit, Vector Laboratories)
applied for 45 min at room temperature. After two further buffer washes,
sections were incubated with universal tertiary antibody (VECTASTAIN
ABC Standard kit, Vector Laboratories) for 30 min at room temperature.
They were then washed twice in buffer and reaction product visualized
using diaminobenzidine chromogen and counterstained with Gill's
hematoxylin.
RESULTS
hBD-1 and hBD-2 genes are expressed in cultured skin
keratinocytes and normal skin but not mesenchymal
cells Reverse transcription±PCR using hBD-1 and hBD-2 gene-
speci®c primers con®rmed that both b defensins are expressed in
primary skin keratinocytes and normal skin. hBD-1 and hBD-2
transcripts were not detectable in ®broblasts or the mesenchymal
HT1080 ®brosarcoma cell line. In order to quantify transcript
abundance of hBD-1 and hBD-2, polyadenylated enriched RNA
was analyzed by northern blot analysis. Hybridization with the
hBD-1 probe detected a single hybridizing band of approximately
0.4 kb in primary keratinocyte culture (Fig 1a). Sequential
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hybridization of the same blots with an hBD-2 probe failed to
detect a hybridizing band. No hybridization signal was detected
from RNA isolates of HT1080 ®brosarcoma cells and ®broblasts,
this was in keeping with the reverse transcription±PCR ®ndings for
mesenchymal cells. Although we were able to detect hBD-1 and
hBD-2 transcripts by reverse transcription±PCR in both HaCat and
RTS3b epithelial cells, the absence of a hybridizing band on
northern blot analysis suggests low levels of expression in the cell
lines. Sequence analysis of the ampli®ed products con®rmed that
the sequences ampli®ed were identical to the published cDNA
sequences for hBD.
In order to determine the relative expression of hBD-1 and
hBD-2 in vivo, total RNA was extracted from 25 normal skin
samples and the expression of hBD-1 and hBD-2 in these samples
was examined using semiquantitative reverse transcription±PCR
(Fig 1b). hBD-1 was detected in all but one of the normal skin
samples con®rming our previous ®nding that hBD-1 is constitu-
tively expressed in normal skin. hBD-2 was detected in 18 of the 25
(72%) normal skin samples analyzed. hBD-2 expression was found
in 100% of the facial and foreskin samples analyzed but only 50% of
skin samples from breast and abdomen (Table I).
hBD-1 and hBD-2 transcripts are present in interfollicular
keratinocytes and the epidermal appendages of normal
skin In order to characterize the expression pattern of hBD-1 and
hBD-2 in normal skin we examined a panel of paraformaldehyde
skin samples from different body sites using in-situ hybridization.
RNA integrity in the samples was con®rmed by initially
hybridizing sections with a keratin 14 probe. In situ hybridization
with the anti-sense hBD-1 probe revealed a signal in suprabasal
keratinocytes in all eight skin samples studied. In some samples a
signal was also detected in basal keratinocytes but the intensity of
Figure 1. hBD-1 and hBD-2 expression in normal human skin,
cultured primary keratinocytes and selected cell lines. (a)
Polyadenylated RNA from epithelial and mesenchymal cells as indicated,
was electrophoresed, transferred to nylon membrane and hybridized
sequentially to 32P-labeled hBD-1 and hBD-2 probes. Only unstimulated
cultured keratinocytes express hBD-1 at suf®cient level for detection by
northern blot analysis. hBD-2 expression is not detected. Epithelial cells
(RTS3b) transfected with hBD-1 or hBD-2 were used as respective
hBD-1- and hBD-2-positive controls. (b) Semi-quantitative reverse
transcription±PCR of RNA isolated from skin samples from four
different body sites: facial skin (Face), abdominal skin (Abdo), breast skin
(Breast) and foreskin (F/skin) demonstrating hBD-1 expression in
foreskin, facial, abdominal and breast skin samples. hBD-2 expression is
demonstrated in facial skin and foreskin samples but in only one of two
abdominal skin samples and in one of two breast skin samples. Gli3
control.
Table I.
Body site
hBD-1 mRNA
expression (%)
hBD-2 mRNA
expression (%)
Face 6/6 (100) 6/6 (100)
Foreskin 7/7 (100) 7/7 (100)
Abdomen 4/5 (80) 2/5 (40)
Breast 7/7 (100) 3/7 (43)
Figure 2. hBD-1 and hBD-2 are expressed in interfollicular keratino-
cytes of normal human skin. Breast skin biopsies were processed for in situ
hybridization using anti-sense (a, c) and sense (b, d) probes for both hBD-1 (a,
b) and hBD-2 (c, d). Note stronger signal for hBD-1 and hBD-2 in suprabasal
keratinocytes of the epidermis. Scale bar: 100 mm.
Figure 3. Dot blots indicating speci®city of anti-hbd-1 and anti-
hbd-2 antibodies. One microgram of synthetic and biologic human a
and b defensins were blotted on to Immobilon-P (Millipore). Following
protein transfer, each membrane was immunostained with rabbit
polyclonal anti-hBD-1 or anti-hBD-2 antibody followed by horseradish
peroxidase labeled goat anti-rabbit antibody (Vector Laboratories).
Peptide signal was detected using enhanced chemiluminescence. (ECL
Plus kit, Amersham Pharmacia Biotech). The ®rst membrane (left)
indicates positive immunoreactivity with anti-hBD-1 rabbit polyclonal
antibody. The second membrane (right) indicates positive immuno-
reactivity with anti-hBD-2 rabbit polyclonal antibody.
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staining was signi®cantly less than that of the suprabasal keratino-
cytes. The intensity of staining with the hBD-1 probe varied
between sections and did not always correlate with differences in
the keratin 14 signal intensity. Although background staining was
noted in some sections, the intensity of staining with the anti-sense
probe was always signi®cantly greater than that seen with the sense
probe (Fig 2a, b). hBD-1 transcripts were detected in sweat glands
as previously reported (Fulton et al, 1997) and in sebaceous glands.
hBD-2 transcripts were seen in nine of 11 skin samples studied
(Fig 2c, d). Of these nine positive samples, seven showed strong
staining and two weaker staining. In most samples, transcripts were
localized throughout the Malpighian layer. In some samples a signal
was absent or less intense in basal keratinocytes. As with hBD-1,
hBD-2 transcripts were also detected in sweat glands and sebaceous
glands.
Immunolocalization of hBD-1 and hBD-2 in normal
skin Having established the expression pattern of hBD-1 and
hBD-2 in normal skin we went on to examine hBD-1 and hBD-2
peptide expression using speci®c polyclonal antibodies. For each
antibody, the specimens were treated identically and the
chromogen developed for the same length of time, thereby
allowing analysis of the intensity of the stain in a given tissue for
each antibody, but not between antibodies. Dot blot analysis
showed that the antibodies were speci®c for hBD-1 and hBD-2,
with no cross-reactivity (Fig 3). The speci®city of immunostaining
was con®rmed by the absence of any staining with preimmune
rabbit serum at the same concentration under the same conditions
(Fig 4d).
hBD-1 peptide expression was examined in 14 normal skin
samples. Positive immunostaining was seen in all samples. Eleven of
the 14 samples showed moderate to strong immunostaining and
three samples showed weaker staining. Two distinct patterns of
expression were seen. Some samples showed intense staining of the
upper Malpighian layer and/or stratum corneum (Fig 4a). Others
showed staining evenly distributed throughout the Malpighian
layer and/or stratum corneum (Fig 4b). The differences in staining
pattern could be related to skin site. Foreskin and facial skin were
more likely to show staining in the upper Malpighian layer,
whereas sites such as breast and abdominal skin were more likely to
demonstrate peptide expression throughout the Malpighian layer.
Figure 4. Immunohistochemical demonstration of b defensin
expression in normal human skin. Normal skin samples were
processed with rabbit polyclonal anti-hBD-1 (a±c) and anti-hBD-2
antibody (e) using a standard three-layer immunohistochemical protocol.
hBD-1 expression in facial skin demonstrates intense staining in the
upper Malpighian layer (a), whereas breast skin (b) demonstrates hBD-1
staining throughout the Malpighian layer and stratum corneum. hBD-1
localizes to sweat gland ducts (c). Pre-immune rabbit serum shows no
speci®c staining of the epidermis (d). Foreskin demonstrates intense
hBD-2 staining in the upper Malpighian layers with weaker staining of
keratinocytes in the suprabasal layers (e). Scale bar: 100 mm.
Table II.
Body site
hBD-1 peptide
expression (%)
hBD-2 peptide
expression (%)
Chest 2/9 (22) 1/9 (11)
Abdomen 4/9 (44) 4/9 (44)
Axilla 5/6 (83) 3/6 (50)
Perineum 7/7 (100) 5/6 (83)
Plantar 6/6 (100) 7/7 (100)
Scalp 5/5 (100) 5/5 (100)
Figure 5. Immunohistochemical demonstration of variable b
defensin expression in normal human skin from different body
sites. Post-mortem human skin was processed for immunohistochemistry
with rabbit polyclonal anti-hBD-1 antibody (a±c) and anti-hBD-2
antibody (d±f). Skin sites demonstrated are abdomen (a, d), plantar (b, e),
and perineum (c, f). Abdominal skin sites express moderate levels of
hBD-1 and hBD-2 compared with plantar skin sites (b, e), which
demonstrate rich defensin expression especially in the stratum corneum.
Perineal (c, f) and abdominal (a, d) skin sites demonstrate considerable
variation in defensin expression. Scalp and plantar skin invariably express
both hBD-1 and hBD-2 peptide in all the skin samples studied (b, e).
Scale bar: 100 mm.
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Sweat glands were seen in 11 of the 14 samples and 10 of these
showed positive immunostaining in luminal cells and within the
lumen (Fig 4c).
hBD-2 peptide expression was examined in 15 normal skin
samples. Positive immunostaining was seen in all samples. Thirteen
of the 15 samples showed moderate to strong immunostaining and
two samples showed weaker staining. Sweat glands were seen in 13
of 15 samples, these all showed positive immunostaining in luminal
cells and within the lumen. The pattern of hBD-2 peptide
expression was similar to that seen with hBD-1 antibody in that
peptide was localized to the Malpighian layer and/or stratum
corneum (Fig 4e). As with hBD-1, abdomen and breast samples
usually demonstrated staining throughout the Malpighian layer,
whereas facial skin and foreskin samples were more likely to
demonstrate strong staining of the upper Malpighian layers.
Although the samples showed similar patterns of hBD-1 and
hBD-2 expression, differences in the staining pattern between
antibodies were noted in serial sections, con®rming the ®ndings of
dot blotting that there was no signi®cant cross-reactivity between
hBD-1 and hBD-2 antibodies.
hBD peptides demonstrate regional differences in expres-
sion Studies of normal skin demonstrated interindividual
differences but no signi®cant gender or age variation. Regional
differences were suggested by the data and con®rmed by post-
mortem tissue sampling in which expression of each b defensin
peptide from skin samples from various body sites was investigated.
Marked differences were noted in both frequency and intensity of
positive staining for each peptide at different skin sites (Table II).
Several consistent patterns emerged: scalp and plantar skin
invariably demonstrated hBD-1 and 2 peptide staining and were
especially rich in both hBD-1 and hBD-2 in the stratum corneum.
(Table II, Fig 5b, e). Maximum intensity of peptide staining was
noted in areas where epidermal appendages opened on to the skin
surface (scalp, plantar surface). Skin from the abdomen, chest, and
perineum showed weak or absent staining of b defensin peptides
and demonstrated greatest variability in hBD-2 expression (Fig 5).
DISCUSSION
Anti-microbial peptides are an emerging concept as an innate
defense mechanism of the epithelial barrier (Huttner and Bevins,
1999; Schroder, 1999). Anti-microbial peptides known to be
expressed in human skin include the cathelicidins (Frohm et al,
1997) and secretory leukocyte protease inhibitor (Wingens et al,
1998). In previous studies using reverse transcription±PCR and in
situ hybridization, we and colleagues have established that mRNA
for hBD-1 and hBD-2 is present in normal skin and keratinocytes
(Fulton et al, 1997; Harder et al, 1997). In order to investigate b
defensin expression further in human skin we have carried out an
extensive analysis of b defensin RNA expression in normal skin
samples from different body sites. In parallel with these studies we
have investigated the expression of hBD-1 and hBD-2 peptide and
describe for the ®rst time the pattern of expression of these peptides
in human skin.
Northern blot analysis revealed that hBD-1 transcript is mod-
erately abundant in cultured primary keratinocytes but not detected
in immortalized epithelial cell lines, whereas reverse transcription±
PCR had demonstrated expression of hBD-1 in all epithelial cell
lines. Neither northern analysis nor reverse transcription±PCR
demonstrated expression of hBD-1 in nonepithelial cell lines. It is
likely that the difference between reverse transcription±PCR and
northern blot ®ndings is due to differences in the sensitivities of the
two methods. hBD-1 mRNA was expressed in normal skin, in all
but one of the samples examined, supporting the concept that this
peptide is constitutively expressed in epithelial tissues. In situ
hybridization con®rmed that hBD-1 transcripts are present in
interfollicular skin and in a number of samples the hybridization
signal was noted to be signi®cantly more intense in differentiating
suprabasal keratinocytes. The demonstration of hBD-1 transcripts
within keratinocytes by in situ hybridization excludes the possibility
that the mRNA detected by reverse transcription±PCR is in other
skin cells such as lymphocytes or Langerhans cells. hBD-1
transcripts were noted to be present in sweat glands and sebaceous
glands. This is of interest given previous reports of increased
expression of hBD-1 in tissues such as the pancreas and kidney
tubules (Zhao et al, 1996; Schnapp et al, 1998) that also play a part
in ¯uid secretion and absorption.
The pattern of immunostaining with hBD-1 speci®c anti-sera
was similar to that for hBD-1 transcripts as demonstrated by in situ
hybridization. Peptide was found to be predominately localized to
suprabasal keratinocytes in interfollicular skin and in sweat gland
ducts and sebaceous glands. Whereas hBD-1 transcripts were
frequently found throughout the Malpighian layer, in a signi®cant
number of cases peptide expression was con®ned to the upper
Malpighian layer and/or stratum corneum. One explanation for
this observation is that hBD-1 peptide production is regulated
post-transcriptionally in more differentiated keratinocytes in the
suprabasal layers. An alternative explanation is that the peptide is
present throughout the Malpighian layer but in an inactive form
that is not detectable by the anti-sera that we have available due to
epitope masking or conformational changes. Studies of other
biologically active molecules such as interleukin-1 have revealed
that normal skin can contain large amounts of biologically active
material, in a preformed pool that is not recognized by some anti-
sera (Camp et al, 1990; Wood et al, 1996). hBD-1 is produced as a
prepropeptide and multiple lengths of peptide exist due to variable
amino-terminal processing (36±47 amino acids) (Valore et al,
1998). In contrast to the classical or a defensins, hBD-1 does not
appear to contain an inhibitory pro-region and relatively minor
changes in the amino-terminal sequences can effect hBD-1 anti-
microbial activity leading to speculation that processing may be an
important mechanism for generating biologic diversity. It will be
important in future studies to determine what forms of hBD-1 are
expressed in normal skin, their biologic activities and the mech-
anisms for generating these forms in epithelia.
hBD-2 was ®rst identi®ed in psoriatic scale and the peptide
sequence used to identify the corresponding cDNA. Subsequent
studies have shown that hBD-2 is expressed in many epithelia and
in contrast to hBD-1, is readily inducible in keratinocytes following
exposure to bacteria or lipopolysaccharide. Using reverse transcrip-
tion±PCR we have examined hBD-2 expression in skin from
different body sites and observed differences in transcript expres-
sion. hBD-2 was readily detectable in all foreskin and facial skin
samples, but in only 50% of the breast or abdomen samples
suggesting regional variation in levels of hBD-2 expression between
facial skin/foreskin and breast/abdomen skin. Regional variations
in expression may re¯ect variations in skin ¯ora, cell turnover, or
other factors, such as ultraviolet radiation exposure, which can
activate nuclear factor-kB that regulates hBD-2 transcription.
There is evidence from other studies that expression of the bovine
b defensin, lingual anti-microbial peptide is increased in tissues
constantly exposed to or colonized by microorganisms (Stolzenberg
et al, 1997). In situ hybridization of a panel of normal skin samples
with hBD-2 anti-sense probes revealed a similar expression pattern
to that seen with hBD-1, con®rming that this gene is also expressed
in interfollicular keratinocytes, sweat glands, and sebaceous glands.
Immunostaining using a recently generated polyclonal antibody
to hBD-2 has allowed us to demonstrate for the ®rst time that
hBD-2 peptide is detectable in normal human skin and that there
are differences between body sites. These differences were
con®rmed by post-mortem study in which several distinct patterns
of peptide expression were noted and were consistent for both
hBD-1 and hBD-2. Some sites (scalp, sole) demonstrated intense
immunostaining with both antibodies, whereas others (abdomen,
chest, and perineum) demonstrated more variability with strong
staining in some tissues and absent staining in others. hBD-1
immunostaining was more consistently present than that for
hBD-2. The greater site to site and interindividual variation for
hBD-2 is consistent with the suggestion that hBD-2 is not
constitutive, but a readily inducible anti-microbial peptide. Our
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observation of differences in hBD-1 immunostaining suggests that
the expression level of this peptide is also subject to some form of
regulation.
Our localization of hBD-1 and hBD-2 throughout the
Malpighian layer of normal epidermis is in agreement with
previous studies. Shi et al (1999) have recently localized porcine
b defensin 1, which is most homologous to hBD-2, to a 0.1 mm
thick layer of the corni®ed tips of the ®liform papilla of the tongue.
The localization of both hBD-1 and hBD-2 peptide predominately
to the upper Malpighian layers and/or stratum corneum is in
keeping with the porcine b defensin 1 results and is consistent with
the proposed role of hBD-1 and -2 as effector molecules of the
innate immune system. The b defensins were initially identi®ed by
their anti-microbial activity, yet it is still not clear if the physiologic
concentration of these peptides and the salt and pH conditions of
epithelial surfaces is conducive to anti-microbial activity (Zucht
et al, 1998). Analysis of the super®cial layer of tongue epithelium
has demonstrated porcine b defensin 1 levels of 20±100 mg per ml.
This is of a level predicted to exhibit signi®cant anti-microbial
activity in the conditions encountered in the porcine oral cavity. It
will be important in future studies to investigate the concentration
of hBD-1 and hBD-2 in epidermis in order to determine if these
peptides are present at concentrations that are compatible with an
anti-microbial effect under physiologic conditions. Anti-microbial
peptides, including members of the defensin family are known to
have additional activities such as inhibition of ®brinolysis (Higazi
et al, 1996), mitogenic activity (Murphy et al, 1993), histamine-
releasing activity (Befus et al, 1999), and corticostasis (Shamova et al,
1993). A recent study has demonstrated that hBD-2 is selectively
chemotactic for immature dendritic cells and memory T cells and
that these are mediated by the CCR6 chemokine receptor (Yang
et al, 1999). This observation suggests that the role of b defensins in
human skin may extend beyond a direct anti-microbial effect and
that these molecules may play an essential part in promoting
adaptive immunity, in¯ammation, and wound healing.
In conclusion, the results from this study indicate that hBD-1 and
hBD-2 transcripts are expressed in human skin and that the
corresponding peptides are predominantly localized to the
Malpighian layer of the epidermis. This is consistent with the
hypothesis that b defensins peptides play an essential part in the
innate resistance of human epithelial surfaces to microbial invasion.
It will be important in future studies to determine the role of these
peptides in normal skin physiology as well as in response to
challenges such as bacterial infection and wounding.
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